|  |
| --- |
| **Supplemental Table 2.** Risk**a** of ≥CIN3, stratified by HPV genotype in subjects, ≥21 or ≥25 years, with equivocal or low-grade cytology. |
|  | **ASC-US/LSIL Cytology Combined** | **ASC-US Cytology** | **LSIL Cytology** |
|  | **Wright (2019)**GO; BL [[24](#_ENREF_24)] | **Bonde**c **(2019)**IJC; BL [[22](#_ENREF_22)] | **Berkhof (2006)**CEBP; 18 mo [[25](#_ENREF_25)] | **Wheeler (2006)**JID; 2 yr [[36](#_ENREF_36)] | **Schiffman (2016)**IJC; 3.5 yr [31] | **Wright (2019)**GO; BL [[24](#_ENREF_24)] | **Wheeler (2014)**IJC; 3 yr [[35](#_ENREF_35)] | **Schiffman (2015)**GO; 3.6 yr [[32](#_ENREF_32)] | **Wright (2019)**GO; BL [[24](#_ENREF_24)] | **Wheeler (2014)**IJC; 3 yr [[35](#_ENREF_35)] |
| **HPV GT** | ≥21 yrs | ≥30 yrs | ≥29 yrs | ≥21 yrs | ≥30 yrs | ≥21 yrs | ≥21 yrs | ≥21 yrs | ≥21 yrs | ≥21 yrs |
| **16** | 14.6 (10.5-20.0) | 44.3 (38.7-49.9) | 39.0 (29.0-51.0) | 39.1 (32.9-45.7) | 17.9 (16.2-19.5) | 16.1 (10.4-24.0) | 16.2 (11.4-20.9) | 16.0 (14.1-18.0) | 13.0 (7.8-21.0) | 18.5 (11.5-25.5) |
| **31** | 6.9 (3.4-13.5) | 38.5 (29.9-47.1) | 34.0 (16.0-57.0) | 14.8 (8.1-23.9) | n/r | 7.4 (2.9-17.5) | 8.1 (3.3-12.9) | 7.0 (5.3-9.4) | 6.2 (2.1-16.8) | 6.4 (0.0-13.4) |
| **18** | 4.5 (1.6-12.5) | 36.8 (22.6-50.6) | 13.0 (7.0-53.0) | 6.1 (2.0-13.7) | n/r | 2.9 (0.5-14.5) | 1.7 (0.0-5.0) | 7.4 (5.1-10.7) | 6.5 (1.8-20.7) | 9.7 (0.0-20.1) |
| **33** | n/r | n/r | 21.0 (6.0-52.0) | 14.0 (5.3-27.9) | n/r | n/r | 0.0 | n/r | n/r | 12.6 (0.0-25.9) |
| **58** | n/r | n/r | 0.0 (0.0-26.0) | 13.4 (6.3-24.0) | n/r | n/r | 2.9 (0.0-6.8) | n/r | n/r | 4.6 (0.0-10.9) |
| **33/58** | 1.9 (0.5-6.8) | 30.9 (20.9-41.3) | n/r | n/r | n/r | 2.0 (0.4-10.3) | n/r | 7.1 (5.1-9.6) | 1.9 (0.3-10.1) | n/r |
| **52** | 2.7 (1.1-6.8) | 16.8 (7.5-29.1) | 8.0 (0.0-46.0) | 7.3 (3.4-13.3) | n/r | 4.1 (1.6-10.0) | 3.2 (0.0-6.7) | 4.3 (3.2-5.9) | 0.0 (0.0-7.4) | 9.2 (0.0-21.3) |
| **45** | 1.9 (0.3-10.1) | 14.7 (4.3-28.4) | 7.0 (0.0-43.0) | 9.8 (2.7-23.1) | n/r | 0.0 (0.0-10.7) | 6.0 (0.0-14.2) | 3.9 (1.9-7.7) | 5.0 0.(9-23.6) | 8.7 (0.0-25.0) |
| **35** | n/r | n/r | 10.0 (0.0-70.0) | 7.8 (2.6-17.3) | n/r | n/r | 1.5 (0.0-4.5) | n/r | n/r | 0.0 |
| **39** | n/r | n/r | 10.0 (0.0-57.0) | 8.5 (2.4-20.4) | n/r | n/r | 1.9 (0.0-4.4) | n/r | n/r | 0.0 |
| **68** | n/r | n/r | 0.0 (0.0-41.0) | 7.7 (0.9-25.1) | n/r | n/r | 0.0 | n/r | n/r | 0.0 |
| **35/39/68** | 1.5 (0.5-4.2) | 13.1 (5.5-22.9) | n/r | n/r | n/r | 2.7 (0.9-7.6) | n/r | 1.6 (1.0-2.3) | 0.0 (0.0-4.0) | n/r |
| **51** | 1.1 (0.2-5.8) | 14.2 (4.4-26.8) | 5.0 (0.0-32.0) | 5.6 (1.8-12.6) | n/r | 2.1 (0.4-10.9) | 0.0 | 2.7 (1.7-4.5) | 0.0 (0.0-7.9) | 0.8 (0.0-2.4) |
| **56** | n/r | n/r | 6.0 (0.0-40.0) | 1.9 (0.0-9.9) | n/r | n/r | 0.0 | n/r | n/r | 1.4 (0.0-4.2) |
| **59** | n/r | n/r | 0.0 (0.0-84.0) | 0.0 (0.0-8.2) | n/r | n/r | 2.4 (0.0-5.6) | n/r | n/r | 0.0 |
| **66** | n/r | n/r | 0.0 (0.0-31.0) | 3.8 (0.5-13.2) | n/r | n/r | n/r | n/r | n/r | n/r |
| **56/59/66** | 0.0 (0.0-1.9) | 1.9 (0.1-7.0) | n/r | n/r | n/r | 0.0 (0.0-4.3) | n/r | 1.3 (0.7-2.3) | 0.0 (0.0-3.4) | n/r |
| **Any HPV pos** | 4.4 (3.4-5.8) | n/r | 21.0 (16.0-27.0) | 2.4 (1.7-3.3) | 4.7 (3.5-6.1) | 5.1 (3.6-7.1) | 4.1b | 3.0 (2.4-3.7) | 3.7 (2.4-5.6) | 4.4b |
| **HPV neg** | 0.4 (0.2-1.0) | n/r | n/r | n/r | 0.3 (0.2-0.4) | 0.3 (0.1-0.9) | 0.1 b | n/r | 1.3 (0.4-4.5) | 0.5b |
| **Abbreviations:** ≥CIN3, cervical intraepithelial neoplasia, grade 3 or worse; HPV, human papillomavirus; ASC-US, atypical squamous cells-undetermined significance; LSIL, low-grade squamous intraepithelial lesion; GT, genotype; yrs, years; n/r, not reported; pos, positive; neg, negative; GO, Gynecologic Oncology; IJC, International Journal of Cancer; CEBP, Cancer Epidemiology, Biomarkers & Prevention; JID, Journal of Infectious Disease; BL baseline |
|  |
| aRisk listed as percent value with corresponding lower and upper confidence intervals (95%) in parenthesesb95% confidence interval not listed in source articlecRepresents a colposcopy referral population with the following overall cytology prevalence values: negative for intraepithelial lesions and malignancies, 9.2%; atypical squamous cells-undetermined significance, 12.5%; low-grade squamous intraepithelial lesions, 22.1%; atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion, 5.3%; high-grade squamous intraepithelial lesion, 49.0%; atypical glandular cells, 0.5%; atypical glandular cells-favor neoplastic; squamous cell carcinoma, 0.5%; adenocarcinoma, 0.8% |